Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Anti Reverse Cap Analog in mRNA Assays
2026-08-23
Anti Reverse Cap Analog (ARCA) improves orientation-controlled mRNA capping and supports more consistent translation initiation. This article connects cap chemistry with assay design, LNP delivery, and translational interpretation using insights from a targeted mRNA stroke study.
-
Tomivosertib in Acute Myeloid Leukemia
2026-08-22
Suarez and colleagues evaluated Tomivosertib as a highly selective MNK1/2 inhibitor in acute myeloid leukemia, linking inhibition of eIF4E Ser209 phosphorylation to reduced leukemia-cell viability and progenitor colony formation. The study also found synergistic anti-leukemic activity with Venetoclax and used mass spectrometry to identify candidate MNK1/2-associated proteins without disrupting MNK2–RAPTOR–mTOR complexes.
-
HPF (Hydroxyphenyl Fluorescein) Lab Guide
2026-08-22
Learn how HPF (Hydroxyphenyl Fluorescein), SKU C3384, can add selective highly reactive oxygen species detection to cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers probe specificity, optical settings, controls, storage, interpretation, and practical product-selection criteria.
-
TCAIM Reprograms Mitochondrial OGDH Proteostasis
2026-08-21
Wang et al. identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The study reveals that mitochondrial proteostasis can directly tune a rate-limiting metabolic enzyme, suppressing OGDH complex activity and altering carbohydrate catabolism in cells and mice.
-
TaqI Restriction Endonuclease Protocol Guide
2026-08-20
TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the TCGA recognition sequence. It is suited to research workflows requiring sticky-end DNA manipulation, but it should not be used for diagnostic or medical applications without separate validation.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Assay Design
2026-08-20
Discover how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody supports interpretable immunofluorescence assay design in rheumatoid arthritis research. This article connects Cy3-based detection with pathway validation, spatial biology, controls, and evidence-aware experimental decisions.
-
Protease Inhibitor Cocktail EDTA-Free: Workflow Guide
2026-08-19
K1010 helps limit endogenous proteolysis during protein extraction and sample preparation with a broad-spectrum inhibitor mixture supplied as a 100X concentrate in DMSO. Its EDTA-free formulation is suited to phosphorylation-sensitive and divalent-cation-dependent workflows, but it should not be treated as a universal substitute for rapid cooling, validated lysis conditions, or assay-specific controls.
-
nor-Binaltorphimine dihydrochloride: KOR Assays
2026-08-19
Explore how nor-Binaltorphimine dihydrochloride can convert circuit-level KOR biology into better-controlled opioid receptor antagonist assays. This article explains the laterality and duration findings of a 2023 Cell Reports study and translates them into practical decisions for pain modulation research.
-
LY294002 in Reliable Cell Viability Assays
2026-08-18
Learn how LY294002 (SKU A8250) can improve the interpretation of PI3K-dependent viability, proliferation, apoptosis, and autophagy experiments. This scenario-based guide covers mechanism, dosing, solvent handling, assay controls, cross-domain interpretation, and practical product-selection criteria.
-
Iptacopan (LNP023) in Complement Assays
2026-08-18
Learn how Iptacopan (LNP023), SKU C8699, can improve the interpretation of cell viability, proliferation, and cytotoxicity experiments involving complement activation. This scenario-based guide connects factor B inhibition with assay design, serum compatibility, dose selection, data interpretation, and practical product evaluation.
-
Trelagliptin succinate: Chondrocyte Assays
2026-08-17
Trelagliptin succinate, also known as SYR-472 succinate, connects selective DPP-4 enzyme inhibition with practical workflows for glucose metabolism, inflammatory cartilage biology, and signaling studies. This guide translates the AMPK/SOX-9 chondrocyte evidence into dose selection, assay controls, troubleshooting, and translational experiment design.
-
GRA12 and Cross-Strain Toxoplasma Virulence
2026-08-17
A recent preprint used pooled in vivo CRISPR-Cas9 screens across parasite strains and mouse backgrounds to identify GRA12 as a broadly required Toxoplasma gondii virulence factor. Follow-up experiments connect GRA12 loss to parasitophorous-vacuole collapse, host-cell necrosis, and a conserved protective function among related coccidian parasites.
-
JXY, TLR4, and M1 Polarization in CAC
2026-08-16
Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting macrophages toward an M1-like phenotype through TLR4-associated signaling. The study combines an orthotopic cancer model with macrophage assays, providing a preclinical framework for studying immune-microenvironment control of CAC rather than focusing only on tumor-cell growth.
-
Anti Reverse Cap Analog for smRNA Workflows
2026-08-15
Anti Reverse Cap Analog helps researchers build directionally capped synthetic mRNAs for stronger translation initiation and more consistent protein expression. This guide connects ARCA-enabled in vitro transcription with a transgene-free hiPSC-to-oligodendrocyte workflow, while providing practical optimization and troubleshooting guidance.
-
How In Vitro Assays Resolve Cancer Drug Responses
2026-08-14
Hannah Schwartz’s dissertation shows that relative viability and fractional viability are not interchangeable measures: one combines proliferative arrest with death, whereas the other more specifically reflects cell killing. This distinction provides a practical framework for interpreting anticancer experiments, including studies of growth-inhibitory agents such as Everolimus (RAD001).